Advances in the targeted therapy of liposarcoma

References

• DoddLGUpdate on liposarcoma: a review for cytopathologistsDiagn Cytopathol2012401122113121932353
   PubMed Web of Science ®Google Scholar
• MatushanskyIHernandoESocciNDA developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomasAm J Pathol20081721069108018310505
   PubMed Web of Science ®Google Scholar
• FletcherCDMBridgeJAHogendoornPCWMertensFWorld Health Organization Classification of Tumours of Soft Tissue and Bone4th edLyonIARC Press2013
   Google Scholar
• FletcherCDMUnniKKMertensFWorld Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and BoneLyonIARC Press20023544
   Google Scholar
• SteenSStephensonGCurrent treatment of soft tissue sarcomaProc (Bayl Univ Med Cent)20082139239618982082
   PubMedGoogle Scholar
• SleijferSOualiMvan GlabbekeMPrognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Eur J Cancer201046728319853437
   PubMed Web of Science ®Google Scholar
• JohnsonKABrownPHDrug development for cancer chemoprevention: focus on molecular targetsSemin Oncol20103734535820816505
   PubMed Web of Science ®Google Scholar
• SingerSAntonescuCRRiedelEBrennanMFHistologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcomaAnn Surg200323835837014501502
   PubMed Web of Science ®Google Scholar
• ZagarsGKBalloMTPistersPWPollockREPatelSRBenjaminRSSurgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapyCancer2003972544255312733154
   PubMed Web of Science ®Google Scholar
• KalluriKWeinbergRAThe basics of epithelia–mesenchymal transitionJ Clin Invest20091191420142819487818
   PubMed Web of Science ®Google Scholar
• WangZLiYAhmadATargeting miRNAs involved in cancer stem cells and EMT regulation: an emerging concept in overcoming drug resistanceDrug Resist Updat20101310911820692200
   PubMed Web of Science ®Google Scholar
• AntonescuCRTschernyavskySJDecusearaRPrognostic impact of P53 status TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 casesClin Cancer Res200173977398711751490
   PubMed Web of Science ®Google Scholar
• FioreMGrossoFLo VulloSMyxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institutionCancer20071092522253117510918
   PubMed Web of Science ®Google Scholar
• PatelSRBurgessMAPlagerCPapadopoulosNELinkeKABenjaminRSMyxoid liposarcoma. Experience with chemotherapyCancer199474126512698055448
   PubMed Web of Science ®Google Scholar
• GuadagnoloBAZagarsGKBalloMTExcellent local control rates and distinctive patterns of failure inmyxoid liposarcoma treated with conservation surgery and radiotherapyInt J Radiat Oncol Biol Phys20087076076517892916
   PubMed Web of Science ®Google Scholar
• JonesRLFisherCAl-MuderisOJudsonIRDifferential sensitivity of liposarcoma subtypes to chemotherapyEur J Cancer2005412853286016289617
   PubMed Web of Science ®Google Scholar
• NishioJContributions of cytogenetics and molecular cytogenet-ics to the diagnosis of adipocytic tumorsJ Biomed Biotechnol2011201152406721274402
   PubMedGoogle Scholar
• ConyersRYoungSThomasDMLiposarcoma: molecular genetics and therapeuticsSarcoma2011201148315421253554
   PubMedGoogle Scholar
• NishioJIwasakiHNabeshimaKNaitoMCytogenetics and molecular genetics of myxoid soft-tissue sarcomasGenet Res Int2011201149714822567356
   PubMedGoogle Scholar
• SuzukiKMatsuiYEndoKMyxoid liposarcoma with EWS–CHOP type 1 fusion geneAnticancer Res2010304679468321115923
   PubMed Web of Science ®Google Scholar
• HornickJLBosenbergMWMentzelTMcMenaminMEOliveiraAMFletcherCDPleomorphic liposarcoma: clinicopathologic analysis of 57 casesAm J Surg Pathol2004281257126715371941
   PubMed Web of Science ®Google Scholar
• GhadimiMPLiuPPengTPleomorphic liposarcoma: clinical observations and molecular variablesCancer20111175359536921598240
   PubMed Web of Science ®Google Scholar
• PedeutourFForusACoindreJMStructure of the supernumerary ring and giant rod chromosomes in adipose tissue tumorsGenes Chromosomes Cancer19992430419892106
   PubMed Web of Science ®Google Scholar
• MertensFFletcherCDDal CinPCytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhologyGenes Chromosomes Cancer19982216e259591630
   PubMed Web of Science ®Google Scholar
• RosaiJAkermanMDal CinPCombined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group)Am J Surg Pathol1996201182e98827023
   PubMed Web of Science ®Google Scholar
• ItalianoABianchiniLKeslairFHMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent ampliconInt J Cancer20081222233224118214854
   PubMed Web of Science ®Google Scholar
• WeaverJDowns-KellyEGoldblumJRFluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasmsMod Pathol20082194394918500263
   PubMed Web of Science ®Google Scholar
• AleixoPBHartmannAAMenezesICMeurerRTOliveiraAMCan MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumoursJ Clin Pathol2009621127113519946100
   PubMed Web of Science ®Google Scholar
• MomandJWuHHDasguptaGMDM2-master regulator of the p53 tumor suppressor proteinGene2000242152910721693
   PubMed Web of Science ®Google Scholar
• TeodoroJGEvansSKGreenMRInhibition of tumor angiogenesis by p53: a new role for the guardian of the genomeJ Mol Med2007851175118617589818
   PubMed Web of Science ®Google Scholar
• FreedmanDAWuLLevineAJFunctions of the MDM2 oncoproteinCell Mol Life Sci1999559610710065155
   PubMed Web of Science ®Google Scholar
• Juven-GershonTOrenMMdm2: the ups and downsMol Med19995718310203572
   PubMed Web of Science ®Google Scholar
• LoughranOLa ThangueNBApoptotic and growthpromoting activity of E2F modulated by MDM2Mol Cell Biol2000202186219710688665
   PubMed Web of Science ®Google Scholar
• OrtegaSMalumbresMBarbacidMCyclin D-dependent kinases, INK4 inhibitors and cancerBiochim Biophys Acta20021602738711960696
   PubMed Web of Science ®Google Scholar
• WeinbergRAThe retinoblastoma protein and cell cycle controlCell1995813233307736585
   PubMed Web of Science ®Google Scholar
• BellacchioEPaggiMGUnderstanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machineryJ Cell Physiol201322828529122718244
   PubMed Web of Science ®Google Scholar
• LlanosSEfeyanAMonsechJDominguezOSerranoMHigh-throughput loss-of-function screening identifies novel p53 regulatorsCell Cycle200651880188516929179
   PubMed Web of Science ®Google Scholar
• ParkJHRoederRGGAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferationMol Cell Biol2006264006401616705155
   PubMed Web of Science ®Google Scholar
• BarretinaJTaylorBSBanerjiSSubtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNat Genet20104271572120601955
   PubMed Web of Science ®Google Scholar
• SantariusTShipleyJBrewerDStrattonMRCooperCSA census of amplified and overexpressed human cancer genesNat Rev Cancer201010596420029424
   PubMed Web of Science ®Google Scholar
• PikorLALockwoodWWThuKLYEATS4 is a novel oncogene amplified in non–small cell lung cancer that regulates the p53 pathwayCancer Res201373247301731224170126
   PubMed Web of Science ®Google Scholar
• ChibonFMarianiODerréJA subgroup of malignant fibrous histiocytomas in associated with genetic changes similar to those of well-differentiated liposarcomasCancer Genet Cytogenet2002139242912547153
   PubMedGoogle Scholar
• ChibonFMarianiODerreJASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplificationsGenes Chromosomes Cancer200440323715034865
   PubMed Web of Science ®Google Scholar
• CastriotaGThompsonGMLinYSchererPEMollerDEBergerJPPeroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoproteinCell Biol Int20073158659117240171
   PubMed Web of Science ®Google Scholar
• MarianiOBrennetotCCoindreJMJUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomasCancer Cell20071136137417418412
   PubMed Web of Science ®Google Scholar
• SantoroSWJoyceGFA general purpose RNA-cleaving DNA enzymeProc Natl Acad Sci U S A199794426242669113977
   PubMed Web of Science ®Google Scholar
• DassCRGallowaySJClarkJCKhachigianLMChoongPFInvolvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacyCancer Biol Ther200871297130118497564
   PubMed Web of Science ®Google Scholar
• CoindreJMPédeutourFAuriasAWell-differentiated and dedif-ferentiated liposarcomasVirchows Arch201045616717919688222
   PubMed Web of Science ®Google Scholar
• ArugaJYokotaNHashimotoMFuruichiTFukudaMMikoshibaKA novel zinc finger protein, Zic, is involved in neurogenesis, especially in the cell lineage of cerebellar granule cellsJ Neurochem199463188018907931345
   PubMed Web of Science ®Google Scholar
• MaurusDHarrisWAZic-associated holoprosencephaly: zebrafish ZIC1 controls midline formation and forebrain patterning by regulating Nodal, Hedgehog, and retinoic acid signalingGenes Dev2009231461147319528322
   PubMed Web of Science ®Google Scholar
• PourebrahimRVan DamKBautersMZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferationsFEBS Lett2007581265122512617936758
   PubMed Web of Science ®Google Scholar
• MerzdorfCSEmerging roles for zic genes in early developmentDev Dyn2007236492294017330889
   PubMed Web of Science ®Google Scholar
• BrillEGobbleRAngelesCZIC1 overexpression is oncogenic in liposarcomaCancer Res201070176891690120713527
   PubMed Web of Science ®Google Scholar
• PengTZhangPLiuJAn experimental model for the study of well differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptorsLab Invest201191339240321060307
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet20063681329133817046465
   PubMed Web of Science ®Google Scholar
• LanckohrCKasprzynskiAKlein-HitpassLIdentification of genes over-expressed in myxoid/round cell liposarcoma DNA microarray analysis and immunohistochemical correlationPathologe201031606619823827
   PubMed Web of Science ®Google Scholar
• AntonescuCRElahiAHumphreyMSpecificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomasJ Mol Diagn2000213213811229517
   PubMed Web of Science ®Google Scholar
• KatarinaEHelenaWChristinaKThe myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cellsAm J Pathol200616851642165316651630
   PubMed Web of Science ®Google Scholar
• BaroneMVCrozatATabaeeAPhilipsonLRonDCHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrestGenes Dev1994844534648125258
   PubMed Web of Science ®Google Scholar
• AdelmantGGilbertJDFreytagSOHuman translocation liposarcomaCCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta functionJ Biol Chem199827315574155819624148
   PubMed Web of Science ®Google Scholar
• KurodaMWangXSokJInduction of a secreted protein by the myxoid liposarcoma oncogeneProc Natl Acad Sci U S A1999965025503010220412
   PubMed Web of Science ®Google Scholar
• AnderssonMKGoranssonMOlofssonAAnderssonCAmanPNuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loopBMC Cancer20101024920515481
   PubMed Web of Science ®Google Scholar
• Perez-ManceraPABermejo-RodriguezCSanchez-MartinMAbolloJimenezFPintadoBSanchez-GarciaIFUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4EPLoS One20083e256918596980
   PubMed Web of Science ®Google Scholar
• GöranssonMEliasEStåhlbergAMyxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expressionInt J Cancer2005115455656015688424
   PubMed Web of Science ®Google Scholar
• OikawaKTanakaMItohSA novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expressionBr J Cancer2012106121976197922588557
   PubMed Web of Science ®Google Scholar
• Pérez-ManceraPABermejo-RodríguezCSánchez-MartínMAbollo-JiménezFPintadoBSánchez-GarcíaIFUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4EPLoS One20083e256918596980
   PubMed Web of Science ®Google Scholar
• RappTBYangLConradEU3rdMandahlNChanskyHARNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cellsJ Orthop Res200220472372912168660
   PubMed Web of Science ®Google Scholar
• WangHIakovaPWildeMC/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4Mol Cell20018481782811684017
   PubMed Web of Science ®Google Scholar
• AntonescuCRElahiAHealeyJHMonoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangementsClin Cancer Res200062788279310914725
   PubMed Web of Science ®Google Scholar
• WorchJCyrusJGoldsbyRMatthayKKNeuhausJDuBoisSGRacial differences in the incidence of mesenchymal tumors associated with EWSR1 translocationCancer Epidemiol Biomarkers Prev201120344945321212061
   PubMed Web of Science ®Google Scholar
• Pérez-ManceraPASánchez-GarcíaIUnderstanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a modelSemin Cancer Biol20051520621415826835
   PubMed Web of Science ®Google Scholar
• RodriguezRRubioRGutierrez-ArandaIFUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cellsStem Cells20112917919221732477
   PubMed Web of Science ®Google Scholar
• SuzukiKMatsuiYHigashimotoMMyxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cellsPLoS One201275e3668222570737
   PubMed Web of Science ®Google Scholar
• LoPiccoloJBlumenthalGMBernsteinWBDennisPATargeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerationsDrug Resist Updat200811325018166498
   PubMed Web of Science ®Google Scholar
• HuangCHMandelkerDSchmidt-KittlerOThe structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutationsScience20073181744174818079394
   PubMed Web of Science ®Google Scholar
• BennettKLHackansonBSmithLTTumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinomaCancer Res2007674657466417510391
   PubMed Web of Science ®Google Scholar
• SaladinRFajasLDanaSHalvorsenYDAuwerxJBriggsMDifferential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesisCell Growth Differ19991043489950217
   PubMedGoogle Scholar
• WuYVOkadaTDeCarolisPRestoration of C/EBPα in dedif-ferentiated liposarcoma induces G2/M cell cycle arrest and apoptosisGenes Chromosomes Cancer201251431332722170698
   PubMed Web of Science ®Google Scholar
• TontonozPSingerSFormanBMTerminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptorProc Natl Acad Sci U S A1997942372418990192
   PubMed Web of Science ®Google Scholar
• DemetriGDFletcherCDMuellerEInduction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcomaProc Natl Acad Sci U S A1999963951395610097144
   PubMed Web of Science ®Google Scholar
• GobbleRMQinLXBrillERExpression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesisCancer Res20117172697270521335544
   PubMed Web of Science ®Google Scholar
• GermanoGFrapolliRSimoneMAntitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cellsCancer Res2010702235224420215499
   PubMed Web of Science ®Google Scholar
• KimVNNamJWGenomics of microRNATrends Genet200632216517316446010
   PubMed Web of Science ®Google Scholar
• CalinGADumitruCDShimizuMFrequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemiaProc Natl Acad Sci U S A20022499155241552912434020
   PubMed Web of Science ®Google Scholar
• SorianoAJubierreLAlmazán-MogaAmicroRNAs as pharmacological targets in cancerPharmacol Res20137531423537752
   PubMed Web of Science ®Google Scholar
• UgrasSBrillEJacobsenASmall RNA sequencing and functional characterization reveals microRNA-143 tumor suppressor activity in liposarcomaCancer Res201171175659566921693658
   PubMed Web of Science ®Google Scholar
• SingerSSocciNDAmbrosiniGGene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposar-comaCancer Res2007676626663617638873
   PubMed Web of Science ®Google Scholar
• ZhangPBillKLiuJMiR-155 Is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signalingCancer Res20127271751176222350414
   PubMed Web of Science ®Google Scholar
• KongWHeLCoppolaMMicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancerJ Biol Chem2010285178691787920371610
   PubMed Web of Science ®Google Scholar
• JiangSZhangH-WLuM-HMicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 geneCancer Res2010703119312720354188
   PubMed Web of Science ®Google Scholar
• XiangXZhuangXJuSmiR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMTOncogene20113033403353
   Web of Science ®Google Scholar
• BorjiginNOhnoSWuWTLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcomaBiochem Biophys Res Commun2012427235536022995304
   PubMed Web of Science ®Google Scholar
• HisaokaMMatsuyamaANakamotoMAberrant calreticulin expression is involved in the dedifferentiation of dedifferentiated liposarcomaAm J Pathol201218052076208322429966
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMvan OosteromATOosterhuisJWPrognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European organization for research and treatment of cancer soft tissue and bone sarcoma group studyJ Clin Oncol19991715015710458228
   PubMed Web of Science ®Google Scholar
• YinAHMiragliaSZanjaniEDAC133, a novel marker for human hematopoietic stem and progenitor cellsBlood199790500250129389720
   PubMed Web of Science ®Google Scholar
• StratfordEWCastroRWennerstromALiposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potentialClin Sarcoma Res20111111122613678
   PubMedGoogle Scholar
• XieHNgDSavinovSNStructure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virusJ Med Chem2007504898490817803292
   PubMed Web of Science ®Google Scholar
• MaerkenTVSpelemanFVermeulenJSmall-molecule MDM2 antagonists as a new therapy concept for neuroblastomaCancer Res2006669646965517018622
   PubMed Web of Science ®Google Scholar
• VassilevLTVuBTGravesBIn vivo activation of the p53 pathway by small-molecule antagonists of MDM2Science200430384484814704432
   PubMed Web of Science ®Google Scholar
• BernsteinPRBuschauerAGeorgGITopics in Medicinal ChemistryHeidelberg, New York, Dordrecht, LondonSpringer2012
   Google Scholar
• OhnstadHOCastroRSunJCorrelation of TP53 and MDM2 genotypes with response to therapy in sarcomaCancer201311951013102223165797
   PubMed Web of Science ®Google Scholar
• PolagerSGinsbergDp53 and E2f: partners in life and deathNat Rev Cancer2009973874819776743
   PubMed Web of Science ®Google Scholar
• CassierPALabidi-GalySIHeudelPTherapeutic pipeline for soft-tissue sarcomaExpert Opin Pharmacother201112162479249121913865
   PubMed Web of Science ®Google Scholar
• Ray-CoquardIBlayJYItalianoAEffect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyLancet Oncol201213111133114023084521
   PubMed Web of Science ®Google Scholar
• ConstantinidouAPollackSMJonesRLMDM2 inhibition in liposarcoma: a step in the right directionLancet Oncol201213111070107123084518
   PubMed Web of Science ®Google Scholar
• YuanYLiaoYMHsuehCTMirshahidiHRNovel targeted therapeutics: inhibitors of MDM2, ALK and PARPJ Hematol Oncol2011411621504625
   PubMed Web of Science ®Google Scholar
• CheokCFVermaCSBaselgaJLaneDPTranslating p53 into the clinicNat Rev Clin Oncol201181253720975744
   PubMed Web of Science ®Google Scholar
• StoneASutherlandRLMusgroveEAInhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeuticsCrit Rev Oncog20121717519822471707
   PubMedGoogle Scholar
• RizzolioFTuccinardiTCaligiuriILucchettiCGiordanoACDK inhibitors: from the bench to clinical trialsCurr Drug Targets20101127929020210753
   PubMed Web of Science ®Google Scholar
• D’AdamoDRScheuKAndersonSEA phase I trial of doxorubicin and flavopiridol in soft tissue sarcomaJ Clin Oncol20062418S, June 20 suppl9523 [ASCO Annual Meeting Proceedings (Post-Meeting Edition)]
   Google Scholar
• SchwartzGKLoRussoPMDicksonMAPhase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)Br J Cancer20111041862186821610706
   PubMed Web of Science ®Google Scholar
• MorrisDGBramwellVHTurcotteRA phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcomaSarcoma20066437417
   Google Scholar
• MenuEGarciaJHuangXA novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma modelCancer Res2008685519552318632601
   PubMed Web of Science ®Google Scholar
• BaughnLBDi LibertoMWuKA novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6Cancer Res2006667661766716885367
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res200911R7719874578
   PubMed Web of Science ®Google Scholar
• ErbaEBergamaschiDBassanoLEcteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of actionEur J Cancer2001379710511165136
   PubMed Web of Science ®Google Scholar
• Di GiandomenicoSFrapolliRBelloEMode of action of trabectedin in myxoid liposarcomasOncogene201333445201521024213580
   PubMed Web of Science ®Google Scholar
• GrossoFJonesRLDemetriGDEfficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyLancet Oncol2007859560217586092
   PubMed Web of Science ®Google Scholar
• GrossoFSanfilippoRVirdisETrabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesAnn Oncol2009201439144419465423
   PubMed Web of Science ®Google Scholar
• CharytonowiczETerryMCoakleyKPPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcomaJ Clin Invest201212288689822293175
   PubMed Web of Science ®Google Scholar
• ForniCMinuzzoMVirdisETrabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumorsMol Cancer Ther2009844945719190116
   PubMed Web of Science ®Google Scholar
• BlayJYCasaliPNietoATanovićALe CesneAEfficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcomaFuture Oncol2014101596823987833
   PubMed Web of Science ®Google Scholar
• GronchiABuiBNBonvalotSPhase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaAnn Oncol201223377177621642514
   PubMed Web of Science ®Google Scholar
• BrogginiMMarchiniSFontanaEMonetaDFowstCGeroniCBrostallicin: a new concept in minor groove DNA binder developmentAnticancer Drugs2004151615090736
   PubMed Web of Science ®Google Scholar
• LeahyMRay-CoquardIVerweijJBrostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupEur J Cancer20074330831517095209
   PubMed Web of Science ®Google Scholar
• ShawverLKSlamonDUllrichASmart drugs: tyrosine kinase inhibitors in cancer therapyCancer Cell2002111712312086869
   PubMed Web of Science ®Google Scholar
• ReichertJMValge-ArcherVEDevelopment trends for monoclonal antibody cancer therapeuticsNat Rev Drug Discov2007634935617431406
   PubMed Web of Science ®Google Scholar
• JohnsonBEJännePARationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancerClin Cancer Res2006124436s4440s16857824
   PubMed Web of Science ®Google Scholar
• HirotaSIsozakiKMoriyamaYGain-of-function mutations of c-kit in human gastrointestinal stromal tumorsScience19982795775809438854
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol2010281061106820100962
   PubMed Web of Science ®Google Scholar
• HutsonTEDavisIDMachielsJPEfficacy and safety of pazopanib in patients with metastatic renal cell carcinomaJ Clin Oncol20102847548020008644
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteFDA Approval for Pazopanib Hydrochloride2013 Available from: http://www.cancer.gov/cancertopics/druginfo/fda-pazopanibhydrochlorideAccessed May 10, 2012
   Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043)J Clin Oncol200927193126313219451427
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPEORTC Soft Tissue and Bone Sarcoma GroupPALETTE Study GroupPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• RanieriGMammiMDonato Di PaolaEPazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcomaCrit Rev Oncol Hematol201489232232924041629
   PubMed Web of Science ®Google Scholar
• Van Der GraafWTBlayJChawlaSPPALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy – an EORTC STBSG Global Network Study (EORTC 62072)J Clin Oncol20112915 suppl
   PubMedGoogle Scholar
• RanieriGMammìMDonato Di PaolaEPazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcomaCrit Rev Oncol Hematol201489232232924041629
   PubMed Web of Science ®Google Scholar
• NiederCWiedenmannNAndratschkeNMollsMCurrent status of angiogenesis inhibitors combined with radiation therapyCancer Treat Rev20063234836416713103
   PubMed Web of Science ®Google Scholar
• KaoJPackerSVuHLPhase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary responseCancer20091153571358019536893
   PubMed Web of Science ®Google Scholar
• HsiehCHJengKSLinCCCombination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinomaClin Drug Investig20092916571
   PubMed Web of Science ®Google Scholar
• KasibhatlaMSteinbergPMeyerJErnstoffMSGeorgeDJRadiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinomaClin Genitourin Cancer20075429129417553211
   PubMed Web of Science ®Google Scholar
• PlastarasJPKimSHLiuYYCell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiationCancer Res200767199443945417909054
   PubMed Web of Science ®Google Scholar
• MonkBMasLZarbaJJA randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC)J Clin Oncol20092715S, May 20 suppl5520 [Meeting Abstracts]
   Google Scholar
• GoyalSShahSKhanAJDanishHHafftyBGEvaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanibISRN Oncol201220125 Article ID 896202
   Google Scholar
• PorzioRBellaMARossiGArdizzoniALong-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcomaAnticancer Res20133331061106323482782
   PubMed Web of Science ®Google Scholar
• ChowWAGuoSValdes-AlbiniFNelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1Anticancer Drugs20061789190316940799
   PubMed Web of Science ®Google Scholar
• KimJBSpiegelmanBMADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolismGenes Dev199610109611078654925
   PubMed Web of Science ®Google Scholar
• HortonJDGoldsteinJLBrownMSSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liverJ Clin Invest20021091125113111994399
   PubMed Web of Science ®Google Scholar
• BrunnerTBGeigerMGrabenbauerGGPhase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancerJ Clin Oncol2008262699270618509182
   PubMed Web of Science ®Google Scholar
• PoreNGuptaAKCernigliaGJMaityAHIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cellsNeoplasia2006888989517132220
   PubMed Web of Science ®Google Scholar
• IkezoeTSaitoTBandobashiKYangYKoefflerHPTaguchiHHIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2Mol Cancer Ther2004347347915078991
   PubMed Web of Science ®Google Scholar
• PanJMottMXiBPhase I study of nelfinavir in liposarcomaCancer Chemother Pharmacol20127079179922983015
   PubMed Web of Science ®Google Scholar
• WagnerKDBenchetritMBianchiniLMichielsJFWagnerNPeroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferationJ Pathol2011224457558821598253
   PubMed Web of Science ®Google Scholar
• DebrockGVanhentenrijkVSciotRDebiec-RychterMOyenRVan OosteromAA phase II trial with rosiglitazone in liposarcoma patientsBr J Cancer2003891409141214562008
   PubMed Web of Science ®Google Scholar
• PishvaianMJMarshallJLWagnerAJA phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignanciesCancer20121185403541322570147
   PubMed Web of Science ®Google Scholar
• ManaraMCNicolettiGZambelliDNVP-BEZ235 as a new therapeutic option for sarcomasClin Cancer Res201016253054020068094
   PubMed Web of Science ®Google Scholar
• SmithKBTranLMTamBMNovel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibitionAm J Pathol20131821400141123416162
   PubMed Web of Science ®Google Scholar
• SchöffskiPRay-CoquardILCioffiAEuropean Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesLancet Oncol2011121045105221937277
   PubMed Web of Science ®Google Scholar
• JemalASiegelRXuJWardECancer statisticsCA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar